IRIS
MARCHICA, VALENTINA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 2.408
AS - Asia 1.782
EU - Europa 1.616
SA - Sud America 275
AF - Africa 107
Continente sconosciuto - Info sul continente non disponibili 7
OC - Oceania 2
Totale 6.197
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 2.328
SG - Singapore 756
CN - Cina 539
IT - Italia 316
SE - Svezia 298
IE - Irlanda 290
BR - Brasile 212
DE - Germania 174
HK - Hong Kong 159
VN - Vietnam 104
FI - Finlandia 83
FR - Francia 79
TR - Turchia 79
NL - Olanda 75
ZA - Sudafrica 65
AT - Austria 61
GB - Regno Unito 59
CA - Canada 55
RU - Federazione Russa 40
IN - India 32
AR - Argentina 23
CZ - Repubblica Ceca 22
RO - Romania 21
BD - Bangladesh 20
JP - Giappone 20
BE - Belgio 18
CI - Costa d'Avorio 17
ES - Italia 16
PL - Polonia 15
MX - Messico 13
LT - Lituania 11
UA - Ucraina 11
EC - Ecuador 10
ID - Indonesia 10
IQ - Iraq 9
PY - Paraguay 8
VE - Venezuela 7
AE - Emirati Arabi Uniti 6
CL - Cile 6
EU - Europa 6
PK - Pakistan 6
BG - Bulgaria 5
CO - Colombia 5
KE - Kenya 5
KR - Corea 5
MA - Marocco 5
UZ - Uzbekistan 5
IL - Israele 4
KH - Cambogia 4
CH - Svizzera 3
IR - Iran 3
LU - Lussemburgo 3
MD - Moldavia 3
NG - Nigeria 3
OM - Oman 3
QA - Qatar 3
SC - Seychelles 3
AZ - Azerbaigian 2
CR - Costa Rica 2
DK - Danimarca 2
ET - Etiopia 2
HN - Honduras 2
JM - Giamaica 2
LV - Lettonia 2
MZ - Mozambico 2
PE - Perù 2
PH - Filippine 2
RS - Serbia 2
SM - San Marino 2
SN - Senegal 2
AL - Albania 1
AM - Armenia 1
AU - Australia 1
BH - Bahrain 1
BN - Brunei Darussalam 1
BO - Bolivia 1
BY - Bielorussia 1
BZ - Belize 1
CG - Congo 1
CY - Cipro 1
DM - Dominica 1
DZ - Algeria 1
EE - Estonia 1
GA - Gabon 1
GD - Grenada 1
GT - Guatemala 1
JO - Giordania 1
KI - Kiribati 1
KW - Kuwait 1
KZ - Kazakistan 1
MY - Malesia 1
NP - Nepal 1
PA - Panama 1
PR - Porto Rico 1
PT - Portogallo 1
SK - Slovacchia (Repubblica Slovacca) 1
SY - Repubblica araba siriana 1
TW - Taiwan 1
UY - Uruguay 1
XK - ???statistics.table.value.countryCode.XK??? 1
Totale 6.197
Salva come PNG Salva come JPEG
Città #
Singapore 389
Ashburn 358
Chandler 333
Dublin 286
Santa Clara 186
Hong Kong 158
Dallas 156
Parma 133
Beijing 119
Ann Arbor 93
Shanghai 92
Boardman 85
New York 84
Los Angeles 75
Dearborn 67
Johannesburg 61
Munich 61
Vienna 56
Izmir 54
Nanjing 51
Princeton 45
Ho Chi Minh City 40
Marseille 37
Helsinki 28
São Paulo 28
Wilmington 27
Columbus 25
Bremen 23
Moscow 23
Shenyang 23
Hanoi 22
Toronto 22
Turku 22
Tokyo 19
Brno 18
Abidjan 17
Brussels 17
Buffalo 17
Houston 15
Milan 15
Poplar 15
San Mateo 15
Hebei 14
Jinan 14
Kunming 14
Council Bluffs 13
Düsseldorf 13
Hefei 13
Nanchang 13
Warsaw 13
Frankfurt am Main 12
Kocaeli 12
Montreal 12
The Dalles 12
London 11
Modena 11
Atlanta 10
Denver 10
Focsani 10
Guangzhou 10
Orem 10
Redmond 10
Rome 10
Ankara 9
Brooklyn 9
Chennai 9
Jakarta 9
Nuremberg 9
Stockholm 9
Bologna 8
Changsha 8
Fairfield 8
Jiaxing 8
Ottawa 8
Woodbridge 8
Chicago 7
Norwalk 7
Pune 7
San Francisco 7
Tianjin 7
Zhengzhou 7
Amsterdam 6
Asunción 6
Boston 6
Manchester 6
Phoenix 6
Savignano sul Rubicone 6
Washington 6
Des Moines 5
Dhaka 5
Haiphong 5
Hangzhou 5
Jacksonville 5
Madrid 5
Palermo 5
Rho 5
Rio de Janeiro 5
Seattle 5
Tashkent 5
Biên Hòa 4
Totale 3.902
Salva come PNG Salva come JPEG
Nome #
Dependence on glutamine uptake and glutamine addiction characterize myeloma cells: a new attractive target 179
Bone marrow CX3CL1/Fractalkine is a new player of the pro-angiogenic microenvironment in multiple myeloma patients 178
A simplified sars-cov-2 pseudovirus neutralization assay 176
Neurofibromatosis type I and multiple myeloma coexistence: A possible link? 172
CD14+CD16+ monocytes are involved in daratumumab-mediated myeloma cells killing and in anti-CD47 therapeutic strategy 162
Application of next-generation sequencing for the genomic characterization of patients with smoldering myeloma 161
Novel targets for the treatment of relapsing multiple myeloma 158
Hypoxia-Inducible Factor (HIF)-1 alpha Inhibitionin Myeloma Cells Significantly Increases the Anti-Myeloma Effect of Lenalidomide in Vivo 157
Bone marrow Dikkopf-1 levels are a new independent risk factor for progression in patients with smouldering myeloma 154
Bovine pestivirus is a new alternative virus for multiple myeloma oncolytic virotherapy 148
Expression of CD38 in myeloma bone niche: A rational basis for the use of anti-CD38 immunotherapy to inhibit osteoclast formation 146
Role of 1q21 in multiple myeloma: From pathogenesis to possible therapeutic targets 140
EXPRESSION OF CD38 AND ECTOENZYMES OF THE ADENOSINERGIC PATHWAYS IN MYELOMA BONE NICHE: A RATIONAL BASIS FOR THE USE OF DARATUMUMAB TO TARGET OSTEOCLAST FORMATION IN MULTIPLE MYELOMA 138
LENALIDOMIDE INCREASES HUMAN DENDRITIC CELL MATURATION MODULATING BOTH MONOCYTE DIFFERENTIATION AND MESENCHYMAL STROMAL CELL INHIBITORY PROPERTIES 134
Amlexanox inhibition of TBK1/IKK epsilon Signaling Is a Novel Therapeutic Approach for Multiple Myeloma-Induced Bone Disease. 133
Bone Marrow DKK-1 Levels in Smoldering Multiple Myeloma Patients: A New Independent Risk Factor for Progression 132
Cutaneous localization in multiple myeloma in the context of bortezomib-based treatment: how do myeloma cells escape from the bone marrow to the skin? 131
DEPENDENCE ON GLUTAMINE UPTAKE OF MYELOMA CELLS DELINEATES A NEW ATTRACTIVE THERAPEUTIC STRATEGY 130
Galectin-1 suppression delineates a new strategy to inhibit myeloma-induced angiogenesis and tumoral growth in vivo 130
Myeloma Cells Deplete Bone Marrow Glutamine and Inhibit Osteoblast Differentiation Limiting Asparagine Availability 130
Stem cell architecture drives myelodysplastic syndrome progression and predicts response to venetoclax-based therapy 130
Galectin-1 Is Highly Expressed By Myeloma Cells and the Bone Marrow Microenvironment and Its Suppression Delineates a New Therapeutic in Vitro and in Vivo Strategy in Multiple Myeloma 128
Monoclonal and Bispecific Anti-BCMA Antibodies in Multiple Myeloma 127
Expression Profile of CD38 and Related Ectoenzymes in Myeloma Bone Niche: A Rational Basis for the Use of Daratumumab to Inhibit Osteoclast Formation and Activity 127
IL21R expressing CD14+CD16+ monocytes expand in multiple myeloma patients leading to increased osteoclasts 126
Oncolytic virotherapy and microenvironment in multiple myeloma 124
PD-L1/PD-1 Pattern of Expression Within the Bone Marrow Immune Microenvironment in Smoldering Myeloma and Active Multiple Myeloma Patients 124
The anti-tumoral effect of lenalidomide is increased in vivo by hypoxia-inducible factor (HIF)-1α inhibition in myeloma cells 123
Concomitant primary hyperparathyroidism in patients with multiple myeloma: A possible link? 122
Lenalidomide increases human dendritic cell maturation in multiple myeloma patients targeting monocyte differentiation and modulating mesenchymal stromal cell inhibitory properties 121
Identification of PSMB4 and PSMD4 as novel target genes correlated with 1q21 amplification in patients with smoldering myeloma and multiple myeloma 117
Possible targets to treat myeloma-related osteoclastogenesis 115
Mechanisms of Action of the New Antibodies in Use in Multiple Myeloma 115
The anti-myeloma effect of Lenalidomide is increased by hypoxia-inducible factor (HIF)-1a inhibition in multiple myeloma cells both in vitro and in vivo 113
ILF2 Is a Regulator of RNA Splicing and DNA Damage Response in 1q21-Amplified Multiple Myeloma 112
Oncolytic Virotherapy in Multiple Myeloma: A Possible Alternative Role of Bovine Viruses 110
Lenalidomide Increases Human Dendritic Cell Maturation in Multiple Myeloma Modulating Both Monocyte Differentiation and Mesenchymal Stromal Cell Inhibitory Properties through Ikaros and Casein Kinase 1 Degradation, Respectively 105
Novel Approaches to Improve Myeloma Cell Killing by Monoclonal Antibodies 104
The impact of CD56 expression in smoldering myeloma patients on early progression 102
PD-L1/PD-1 axis in multiple myeloma microenvironment and a possible link with CD38-mediated immune-suppression 98
Assessment of the interlaboratory variability and robustness of JAK2V617F mutation assays: A study involving a consortium of 19 Italian laboratories 90
Overexpression of Pro-Osteoclastogenic Cytokine Receptors and Chemokines By Bone Marrow CD14(+) Monocytes of Multiple Myeloma (MM) Patients As Compared to Smoldering MM (SMM) and Monoclonal Gammopathy of Uncertain Significance (MGUS): Role of Interleukin(IL)-21 Receptor/IL-21 Axis in MM-Induced Osteoclastogenesis 88
Transcriptional and proteomic profiles of bone marrow CD14+ cells in multiple myeloma (MM) compared to smoldering MM and MGUS: overexpression of Interleukin (IL)-21 receptor and its involvement in MM-induced osteoclastogenesis 87
Targeting DNA2 overcomes metabolic reprogramming in multiple myeloma 86
Role of Galectins in Multiple Myeloma. 84
Immune response to SARS-CoV-2 mRNA vaccination and booster dose in patients with multiple myeloma and monoclonal gammopathies: impact of Omicron variant on the humoral response 83
MYELOMA CELLS FROM THE BONE MARROW TO THE SKIN: HOW? 83
The Proteasome Inhibitor Bortezomib Maintains Osteocyte Viability in Multiple Myeloma Patients by Reducing Both Apoptosis and Autophagy: A New Function for Proteasome Inhibitors 82
Molecular Features of the Mesenchymal and Osteoblastic Cells in Multiple Myeloma 79
The Myeloma Cells Escape from Bone Marrow to Skin Extramedullary Localization upon Bortezomib Resistance: Role of CXCR4 79
Author Correction: Stem cell architecture drives myelodysplastic syndrome progression and predicts response to venetoclax-based therapy (Nature Medicine, (2022), 28, 3, (557-567), 10.1038/s41591-022-01696-4) 74
Metabolic features of myeloma cells in the context of bone microenvironment: Implication for the pathophysiology and clinic of myeloma bone disease 68
The Pathophysiology of Myeloma Bone Disease: Role of Osteoblasts and Osteocytes 3
Totale 6.318
Salva come PNG Salva come JPEG
Categoria #
all - tutte 23.856
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 23.856
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021162 0 0 0 0 0 8 15 22 44 28 16 29
2021/2022296 6 10 10 23 6 7 43 35 26 15 19 96
2022/20231.244 129 141 92 100 102 137 50 81 340 14 45 13
2023/2024540 22 43 14 14 37 160 49 11 24 43 26 97
2024/20251.531 27 60 84 140 162 142 106 87 194 119 144 266
2025/20261.768 318 244 362 301 469 74 0 0 0 0 0 0
Totale 6.318